Association between Plasma Osmolality and Case Fatality within 1 Year after Severe Acute Ischemic Stroke

Meng Liu, Yilun Deng, Yajun Cheng, Zilong Hao, Simiao Wu, and Ming Liu
Center of Cerebrovascular Disease, Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.

Purpose: Plasma osmolality, a marker of dehydration, is associated with cardiovascular mortality. We aimed to investigate whether elevated plasma osmolality is associated with case fatality within 1 year after severe acute ischemic stroke.

Materials and Methods: We included severe ischemic stroke patients (defined as National Institutes of Health Stroke Scale ≥15 score) within 24 hours from symptom onset admitted to the Department of Neurology, West China Hospital between January 2017 and June 2019. Admission plasma osmolality was calculated using the equation 1.86*(sodium+potassium)+1.15*glucose+urea+14. Elevated plasma osmolality was defined as plasma osmolality >296 mOsm/kg, indicating a state of dehydration. Study outcomes included 3-month and 1-year case fatalities. Multivariable logistic regression was performed to determine independent associations between plasma osmolality and case fatalities at different time points.

Results: A total of 265 patients with severe acute ischemic stroke were included. The mean age was 71.2±13.1 years, with 51.3% being males. Among the included patients, case fatalities were recorded for 31.7% (84/265) at 3 months and 39.6% (105/265) at 1 year. Elevated plasma osmolality (dehydration) was associated with 3-month case fatality (odds ratio (OR) 1.98, 95% confidence interval (CI) 1.07–3.66, \( p=0.029 \)), but not 1-year case fatality (OR 1.51, 95% CI 0.84–2.72, \( p=0.165 \)), after full adjustment for confounding factors.

Conclusion: Elevated plasma osmolality was independently associated with 3-month case fatality, but not 1-year case fatality, for severe acute ischemic stroke.

Key Words: Plasma osmolality, dehydration, severe acute ischemic stroke, case fatality.

INTRODUCTION

Stroke is the second leading cause of death worldwide.1 In China, the age-standardized mortality of stroke has remained over 100 cases per 100000 people in the recent decades.2 Acute ischemic stroke with an initially severe neurologic deficit has been found to account for 36.4% of all ischemic strokes.3 Severely anterior circulation ischemia is often associated with a large middle cerebral artery (MCA) territory infarction on later neuroimaging, causing a high risk of developing life-threatening brain edema and trans-tentorial herniation on patients.4 Meanwhile, patients frequently have impaired consciousness on presentation due to severe posterior circulation ischemia, which may increase the complexity of initial diagnosis. Due to the detrimental progression, severe acute ischemic stroke both of the anterior and posterior circulation carries high case fatalities in the short and long term.5,6 Given the large burden of stroke mortality and disability, various radiologic, clinical, and biochemical parameters have been researched as predictors of case fatality after stroke.5,6 Under this circumstance, identifying new factors with which to predict the prognosis for this group of patients is of paramount importance for clinicians to optimize management.

Plasma osmolality, reflecting the volume of extracellular flu-
id, serves as an indicator of dehydration. A recent study has shown that older patients (≥65 years old) presenting with acute ischemic stroke have high plasma osmolality levels, which represents a fluid depleted state. Inadequate hydration accompanied by increased blood viscosity and decreased collateral circulation exacerbates brain hypo-perfusion after ischemia. Elevated plasma osmolality has been shown to be a predictor of mortality in cardiovascular diseases, including myocardial infarction and heart failure, but the association between plasma hyperosmolality and case fatality in severe acute ischemic stroke has not been well established. Therefore, the purpose of this study was to investigate the relationship between plasma osmolality and case fatalities at 3 months and 1 year after stroke among patients with severe acute ischemic stroke.

MATERIALS AND METHODS

Study population
We consecutively enrolled patients with ischemic stroke from January 2017 to June 2019 admitted to the Department of Neurology, West China Hospital, Sichuan University. The diagnosis of ischemic stroke was based on clinical characteristics and confirmed by computed tomography (CT) or magnetic resonance imaging (MRI). Severe ischemic stroke was defined as severe neurological deficits with a National Institutes of Health Stroke Scale (NIHSS) score of 15 or above on admission. The inclusion criteria were 1) age ≥18 years, 2) onset to admission time within 24 hours (h), and 3) meeting the clinical criteria of severe ischemic stroke. Patients were excluded if they 1) received osmotic agents like mannitol prior to the first blood draw, 2) presented with other severe complications or comorbidities, such as a malignant tumor and hepatic or renal failure, 3) lacked follow-up neuroimaging data, or 4) had missing follow-up information. The data of eligible patients were extracted from the Chengdu Stroke Registry Database, as described in a previous study. The study was approved by The Biomedical Research Ethics Committee of West China Hospital, Sichuan University [Reference No. 2020 (174)], and informed consent was obtained from the participants or their next of kin.

Data collection
Demographic information and vascular risk factors were documented on admission, including information on age, sex, hypertension, diabetes, hyperlipidemia, atrial fibrillation, previous stroke (previous hemorrhagic and/or ischemic stroke), smoking, and alcohol consumption. Several aspects that reflected the severity of stroke, such as a NIHSS score, impaired consciousness, and large MCA infarction, were also assessed and recorded. The NIHSS score was evaluated on admission and at discharge in the neurology ward by a trained neurological physician according to an international scale. An impaired consciousness was defined as the presence of stupor or coma on admission. Large MCA infarction was defined as the presence of hypo-density covering at least 1/3 of the MCA territory within 6 h or at least 1/2 of the MCA territory beyond 6 h with or without involvement of other arterial territories. All patients had a baseline brain CT performed on admission to exclude intracranial hemorrhage. A follow-up CT or MRI was performed within 7 days after admission or if any neurological deterioration occurred. We also collected potentially dehydration-related clinical characteristics, such as vomiting, dysphagia, and incontinence. The etiology of stroke was classified by the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification. In-hospital treatments analyzed in our study included reperfusion therapy, osmotic therapy, and decompressive craniectomy. Stroke-related infectious complications, including stroke-associated pneumonia and urinary tract infection, were also recorded. The estimated glomerular filtration rate (eGFR) was calculated using the equation eGFR=186*SCr-1.154*AGE-0.203*0.742 [if female]+1.233 [if Chinese].

Blood sample collection and assessment of plasma osmolality
Peripheral-venous blood samples were obtained on admission from the first blood draw prior to any medical intervention. Corresponding biochemical indices were analyzed via an automatic biochemical analyzer in the Department of Laboratory Medicine, West China Hospital. Plasma osmolality was determined by four biochemical components, including plasma sodium (Na⁺), potassium (K⁺), glucose, and urea. Plasma osmolality was calculated based on the Khajuria, et al. formula: plasma osmolality=1.86*(Na' + K') + 1.15*glucose + urea + 14, which provides the best fit between measured and calculated osmolality. In the formula mentioned above, all the units for the plasma constituents are millimoles per liter (mmol/L), and osmolality was expressed as milliosmoles per kilogram (mOsm/kg). Since the cutoff point of 296 mOsm/kg based on the A Khajuria equation was reported to have the best diagnostic capability in screening for dehydration status, elevated plasma osmolality was defined as plasma osmolality >296 mOsm/kg, which was consistent with a state of dehydration.

Outcome definitions and assessment
The primary endpoint was 3-month case fatality, and the secondary endpoint was 1-year case fatality. Case fatalities were defined as the proportion of overall death (regardless of cause) occurring within 3 months and 1 year after stroke onset, respectively. All included patients were followed up prospectively by our research team during the first year after stroke via telephone interviews. A structured follow-up form was designed to conduct the follow up. If a patient died, we recorded the date of death or month of death if the specific date of death was not available. Modified Rankin Score (mRS) was evaluated and recorded at 3 months and 1 year after stroke onset.
Statistical analysis
We used descriptive statistics to show baseline characteristics. Continuous variables are expressed as a mean±standard deviation or median (interquartile range) as appropriate. Categorical variables are presented as a frequency and percentage. We conducted Student’s t test or Mann-Whitney U test for continuous variables and the chi-squared test or Fisher’s exact test for categorical variables, when appropriate. To evaluate the effect of plasma osmolality on stroke case fatalities, univariable and multivariable logistic regression models were designed. For controlling confounding factors, both the significant variables in the univariable model and clinically significant variables were included in the multivariable models. To evaluate the robustness of the primary finding, we conducted stratified logistic regression analysis. The differences between subgroups were tested by interaction analysis using a likelihood ratio test. When appropriate, the results are presented as odds ratios (OR) with corresponding 95% confidence intervals (CI). Statistical analyses were performed using SPSS version 21.0 (IBM Corp., Armonk, NY, USA), and figures were drawn by the GraphPad Prism 7 (GraphPad Software Inc, LaJolla, CA, USA). A two side p<0.05 was statistically significant.

RESULTS

Characteristics of the study cohort
From January 2017 to June 2019, 1317 patients within 24 hours after stroke onset were screened in the study, and 319 patients presented with severe acute ischemic stroke. After excluding patients who received osmotic therapy prior to the first blood draw (n=9), patients with a malignant tumor or hepatic or renal failure (n=12), patients with incomplete neuroimaging data (n=14), and patients lacking follow-up information (n=19), we included 265 patients for final analysis. The first blood draw was collected within 0–3 h [46.0% (122/265)], 3–9 h [47.5% (126/265)], 9–12 h [2.6% (7/265)], and 12–24 h [3.8% (10/265)] from stroke onset. Among the included patients, the average age was 71.2±13.1 years, and 51.3% were male. The median NIHSS score on admission was 20 (interquartile range, 17–22).

Characteristics of plasma osmolality levels and case fatalities
Among the 265 subjects, 38.1% (101/265) were found to be dehydrated based on a plasma osmolality >296 mOsm/kg at admission. The characteristics of plasma osmolality levels and case fatalities are presented in Table 1. Patients with elevated plasma osmolality were older and had a higher proportion of diabetes, impaired consciousness, and vomiting. There was a tendency for higher proportions of male sex and hypertension and a higher rate of decompressive craniectomy in the hyper-

| Table 1. Patient Characteristics and Outcomes Stratified according to Plasma Osmolality Levels |
|-------------------------------------------------|-------------------------------------------------|-----------------|--------------|
| Variables                        | Plasma osmolality (mOsm/kg) | <296 | >296 | p value |
|----------------------------------|-----------------------------|------|------|---------|
| Demographics                     |                             | (n=164) | (n=101) |         |
| Age, yr                         | 74 (61–90)                  | 75 (68–84) |      | 0.044 |
| Male                            | 91 (55.5)                   | 45 (44.6) |      | 0.084 |
| Onset to admission, hours       | 4 (3–6)                     | 4 (3–6) |      | 0.987 |
| Vascular risk factors           |                             |       |       |         |
| Hypertension                    | 88 (63.7)                   | 66 (65.3) |      | 0.081 |
| Diabetes                        | 25 (15.2)                   | 37 (36.6) |      | <0.001 |
| Hyperlipidemia                  | 12 (7.3)                    | 8 (7.9) |      | 0.857 |
| Atrial fibrillation             | 93 (56.7)                   | 58 (57.4) |      | 0.909 |
| Previous stroke                 | 23 (14.0)                   | 14 (13.9) |      | 0.970 |
| Smoking                         | 52 (31.7)                   | 23 (22.8) |      | 0.117 |
| Alcohol consumption             | 19 (11.6)                   | 14 (13.9) |      | 0.586 |
| Clinical characteristics        |                             |       |       |         |
| NIHSS on admission              | 19 (17–22)                  | 20 (17–24) |      | 0.142 |
| Impaired consciousness          | 65 (39.6)                   | 53 (52.5) |      | 0.041 |
| Vomiting                        | 21 (12.8)                   | 31 (30.7) |      | <0.001 |
| Dysphagia                       | 9 (5.5)                     | 1 (1.0) |      | 0.125 |
| Incontinence                    | 29 (17.7)                   | 26 (25.7) |      | 0.116 |
| Large MCA infarction            | 76 (46.3)                   | 51 (50.5) |      | 0.511 |
| TOAST classification            |                             |       |       | 0.870 |
| Large-artery atherosclerosis     | 57 (34.8)                   | 36 (35.6) |      |         |
| Small-artery occlusion           | 0 (0)                       | 0 (0) |      |         |
| Cardio-embolism                 | 79 (48.2)                   | 49 (48.5) |      |         |
| Other etiology                  | 4 (2.4)                     | 1 (1) |      |         |
| Undetermined etiology           | 24 (14.6)                   | 15 (14.9) |      |         |
| Treatments during hospitalization |                           |       |       |         |
| Reperfusion therapy             |                             |       |       | 0.683 |
| None                            | 78 (47.6)                   | 52 (51.5) |      |         |
| Thrombolysis only               | 21 (12.8)                   | 16 (15.8) |      |         |
| Thrombectomy only               | 47 (28.7)                   | 23 (22.8) |      |         |
| Thrombolysis and thrombectomy   | 18 (11.0)                   | 10 (9.9) |      |         |
| Osmotic therapy                 | 127 (77.4)                  | 79 (78.2) |      | 0.882 |
| Decompressive craniectomy       | 10 (6.1)                    | 1 (1.0) |      | 0.088 |
| Stroke-associated pneumonia     | 111 (67.7)                  | 77 (76.2) |      | 0.136 |
| Urinary tract infection         | 44 (26.8)                   | 25 (24.8) |      | 0.708 |
| Baseline values for osmolality  |                             |       |       |         |
| Osmolality, mOsm/kg             | 291.1±4.1                   | 300.7±4.0 | <0.001 |
| Sodium, mmol/L                  | 137.4±2.6                   | 140.5±2.0 | <0.001 |
| Potassium, mmol/L               | 3.7±0.4                     | 3.7±0.5 |      | 0.962 |
| Glucose, mmol/L                 | 7.4 (6.2–8.6)               | 8.2 (7.0–11.9) | <0.001 |
| Urea, mmol/L                    | 5.6 (4.7–6.9)               | 7.0 (5.5–8.7) | <0.001 |
| eGFR (mL/min/1.73 m²)           | 109 (90–134)                | 96 (75–113) | <0.001 |
| NIHSS at discharge*             | 14 (10–18)                  | 15 (10–26) | 0.284 |
| Death in hospital               | 12 (7.3)                    | 15 (14.9) |      | 0.049 |
| mRS at 3 months                 | 4 (3–5)                     | 5 (4–6) |      | 0.002 |
| mRS at 1 year                   | 4 (2–6)                     | 6 (3–6) |      | 0.047 |
| Case fatality                   |                             |       |       |         |
| 3 months                        | 40 (24.4)                   | 44 (43.6) |      | 0.001 |
| 1 year                          | 54 (32.9)                   | 51 (50.5) |      | 0.005 |

NIHSS, National Institutes of Health Stroke Scale; MCA, middle cerebral artery; TOAST, Trial of Org 10172 in Acute Stroke Treatment classification; mRS, modified Rankin Score; eGFR, estimated Glomerular Filtration Rate. Data are presented as mean±standard deviation, median (interquartile range) or n (%). Due to death in a hospital, NIHSS at discharge was available only from those alive at discharge.

https://doi.org/10.3349/ymj.2021.62.7.800
osmolality group \( (p=0.084, 0.061, \text{and } 0.088, \text{respectively}) \). Compared with patients in the non-hyperosmolality group, those in the hyperosmolality group had relatively poorer renal function evaluated by eGFR (median 109 vs. 96 mL/min/1.73 m², \( p<0.001 \)). Moreover, patients with elevated plasma osmolality were more likely to have greater levels of plasma sodium, glucose, and urea values (all \( p<0.001 \)). Regarding the short- and long-term functional outcomes assessed by mRS at 3 months and 1 year after stroke onset, patients in the hyperosmolality group had more adverse functional outcomes \( (p=0.002 \text{ and } 0.047, \text{respectively}) \). With regard to case fatalities, patients with elevated plasma osmolality had higher case fatalities both at 3 months and 1 year (all \( p<0.05 \)).

### Association between plasma osmolality and case fatalities

Univariable logistic regression models are shown in Table 2. NIHSS on admission, impaired consciousness, large MCA in-

| Variables                      | 3-month case fatality | 1-year case fatality |
|--------------------------------|-----------------------|----------------------|
|                                | OR (95% CI)           | \( p \) value        | OR (95% CI)       | \( p \) value |
| Demographics                   |                       |                      |                    |              |
| Age, yr                        | 1.01 (0.99–1.04)      | 0.174                | 1.02 (1.00–1.04)   | 0.059        |
| Male                           | 0.99 (0.59–1.67)      | 0.977                | 1.01 (0.62–1.65)   | 0.977        |
| Onset to admission time, hours | 0.96 (0.93–1.00)      | 0.050                | 0.99 (0.96–1.02)   | 0.452        |
| Vascular risk factors          |                       |                      |                    |              |
| Hypertension                   | 1.26 (0.74–2.14)      | 0.394                | 1.30 (0.78–2.14)   | 0.311        |
| Diabetes                       | 1.51 (0.83–2.73)      | 0.177                | 1.47 (0.83–2.61)   | 0.190        |
| Hyperlipidemia                 | 0.92 (0.34–2.48)      | 0.865                | 0.81 (0.31–2.10)   | 0.661        |
| Atrial fibrillation            | 1.01 (0.60–1.70)      | 0.971                | 0.95 (0.58–1.56)   | 0.833        |
| Previous stroke                | 0.90 (0.42–1.92)      | 0.782                | 1.35 (0.67–2.72)   | 0.398        |
| Smoking                        | 0.86 (0.48–1.53)      | 0.603                | 0.81 (0.47–1.40)   | 0.449        |
| Alcohol consumption            | 0.79 (0.35–1.77)      | 0.560                | 0.99 (0.47–2.09)   | 0.977        |
| Clinical characteristics       |                       |                      |                    |              |
| NIHSS on admission             | 1.06 (1.01–1.12)      | 0.023                | 1.06 (1.01–1.12)   | 0.024        |
| Impaired consciousness         | 1.71 (1.01–2.88)      | 0.044                | 1.81 (1.10–2.97)   | 0.020        |
| Vomiting                       | 1.61 (0.86–3.02)      | 0.135                | 2.27 (1.23–4.20)   | 0.009        |
| Dysphagia                      | 0.53 (0.11–2.54)      | 0.425                | 0.64 (0.16–2.54)   | 0.529        |
| Incontinence                   | 1.30 (0.70–2.43)      | 0.404                | 1.79 (0.98–3.26)   | 0.056        |
| Large MCA infarction           | 2.87 (1.67–4.92)      | <0.001               | 2.25 (1.36–3.72)   | 0.002        |
| TOAST classification           |                       |                      |                    |              |
| Large-artery atherosclerosis   | Reference             |                      | Reference         |              |
| Small-artery occlusion         | NA                    |                      | NA                | NA          |
| Cardio-embolism                | 0.60 (0.34–1.08)      | 0.086                | 0.62 (0.36–1.08)   | 0.088        |
| Other etiology                 | 1.16 (0.18–7.27)      | 0.877                | 0.85 (0.14–5.30)   | 0.858        |
| Undetermined etiology          | 1.09 (0.50–2.34)      | 0.836                | 1.34 (0.63–2.83)   | 0.450        |
| Treatments during hospitalization |                       |                      |                    |              |
| Reperfusion therapy            |                       |                      |                    |              |
| None                           | Reference             |                      | Reference         |              |
| Thrombolysis only              | 0.58 (0.24–1.37)      | 0.214                | 0.45 (0.20–1.04)   | 0.600        |
| Thrombectomy only              | 1.40 (0.76–2.55)      | 0.277                | 1.33 (0.74–2.38)   | 0.340        |
| Thrombolysis and thrombectomy  | 0.57 (0.22–1.51)      | 0.260                | 0.56 (0.23–1.37)   | 0.206        |
| Osmotic therapy                | 2.40 (1.17–4.88)      | 0.017                | 2.28 (1.19–4.35)   | 0.013        |
| Decompressive craniectomy      | 0.47 (0.10–2.21)      | 0.336                | 0.56 (0.15–2.16)   | 0.398        |
| Stroke-associated pneumonia    | 3.81 (1.89–7.69)      | <0.001               | 3.80 (2.02–7.14)   | <0.001       |
| Urinary tract infection        | 0.70 (0.38–1.28)      | 0.245                | 0.82 (0.47–1.45)   | 0.503        |
| eGFR (mL/min/1.73 m²)          | 1.00 (0.99–1.00)      | 0.319                | 0.99 (0.99–1.00)   | 0.134        |
| Plasma osmolality (continuous) | 1.08 (1.03–1.13)      | 0.001                | 1.06 (1.02–1.11)   | 0.006        |
| Plasma osmolality (>296 mOsm/kg) | 2.39 (1.41–4.07)      | 0.001                | 2.08 (1.25–3.45)   | 0.005        |

OR, odds ratio; CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; MCA, middle cerebral artery; TOAST, Trial of Org 10172 in Acute Stroke Treatment classification; eGFR, estimated Glomerular Filtration Rate; NA, not available due to limited sample size.

https://doi.org/10.3349/ymj.2021.62.7.600
farction, osmotic therapy, and stroke-associated pneumonia were significantly associated with case fatalities at 3 months and 1 year \((p<0.05)\). Additionally, vomiting was found to be possible confounding factor associated with case fatality at 1 year.

In multivariable logistic regression adjusting for age, male sex, diabetes, NIHSS on admission, impaired consciousness, vomiting, large MCA infarction, osmotic therapy, and stroke-associated pneumonia. A plasma osmolality increase by 1 mOsm/kg was significantly associated with case fatality at 3 months \((OR 1.06, 95\% CI 1.01−1.12, p=0.025)\) (Table 3). When dividing patients into two groups according to hydration status, patients with dehydration (plasma osmolality >296 mOsm/kg) were independently associated with case fatality at 3 months \((OR 1.98, 95\% CI 1.07−3.66, p=0.029)\). Other statistically significant variables related to case fatality at 3 months in multivariable logistic regression were large MCA infarction and stroke-associated pneumonia. With regard to case fatality at 1 year, neither plasma osmolality increase by 1 mOsm/kg nor elevated plasma osmolality achieved statistical significance \((OR 1.04, 95\% CI 0.99−1.09, p=0.144; OR 1.51, 95\% CI 0.84−2.72, p=0.165, respectively)\) after full adjustment for confounding factors.

**Subgroup analysis**

Many factors are known to influence plasma osmolality, such as older age with decreased thirst, diabetes with a poor control of plasma glucose, and osmotic therapy with osmotic diuresis. Meanwhile, large MCA infarction and impaired consciousness are also important factors related to case fatality and dehydration. Considering possible reverse causality mentioned above, we stratified patients according to age groups (<65 years or ≥65 years), diabetes, osmotic therapy, large MCA infarction, and impaired consciousness and further conducted a stratified logistic regression analysis. The model was not adjusted for the stratification variable in each stratified analysis. As shown in Fig. 1, the interactions between these potential modifiers and elevated plasma osmolality (>296 mOsm/kg) on case fatality were not significant \((All p for interaction >0.05)\).

**DISCUSSION**

In this study, we found that among patients with severe acute ischemic stroke, elevated plasma osmolality (>296 mOsm/kg), as a marker of dehydration, was associated with an increased risk of case fatality at 3 months, whereas elevated plasma osmolality seemed to be unrelated to case fatality at 1 year.

Case fatality is regarded as a quality marker of stroke management and is commonly used to document the success of stroke care.27 A previous study reported that the 3-month and 1-year case fatalities of ischemic stroke were 18.4% and 31.6%, respectively.28 Our study demonstrated that case fatalities for severe acute ischemic stroke were 31.7% at 3 months and 39.6% at 1 year. The case fatalities in our study were higher at different time points, compared with other studies. After excluding vari-

---

**Table 3. Multivariable Logistic Regression Analysis between Plasma Osmolality and Case Fatalities**

| Variables                             | 3-month case fatality | 1-year case fatality |
|---------------------------------------|-----------------------|----------------------|
|                                       | OR (95% CI) | \(p\) value | OR (95% CI) | \(p\) value |
| Plasma osmolality (continuous)        | 1.06 (1.01−1.12) | 0.025 | 1.04 (0.99−1.09) | 0.144 |
| Age                                  | 1.00 (0.98−1.03) | 0.759 | 1.01 (0.99−1.03) | 0.343 |
| Male                                 | 0.89 (0.48−1.64) | 0.699 | 0.95 (0.53−1.70) | 0.663 |
| Diabetes                              | 1.17 (0.58−2.36) | 0.666 | 1.26 (0.64−2.47) | 0.500 |
| NIHSS on admission                    | 1.06 (0.99−1.13) | 0.118 | 1.04 (0.98−1.11) | 0.217 |
| Impaired consciousness                | 1.02 (0.52−2.00) | 0.961 | 1.16 (0.61−2.21) | 0.649 |
| Vomiting                              | 1.23 (0.61−2.48) | 0.560 | 2.03 (1.03−3.99) | 0.041 |
| Large MCA infarction                  | 2.49 (1.35−4.59) | 0.003 | 1.80 (1.01−3.19) | 0.046 |
| Osmotic therapy                       | 1.49 (0.66−3.37) | 0.342 | 1.55 (0.74−3.24) | 0.249 |
| Stroke-associated pneumonia           | 2.96 (1.38−6.35) | 0.005 | 3.00 (1.51−5.97) | 0.002 |
| Plasma osmolality (>296 mOsm/kg)      | 1.98 (1.07−3.66) | 0.029 | 1.51 (0.84−2.72) | 0.165 |
| Age                                  | 1.00 (0.98−1.03) | 0.742 | 1.01 (0.99−1.03) | 0.330 |
| Male                                 | 0.92 (0.50−1.70) | 0.790 | 0.98 (0.54−1.75) | 0.931 |
| Diabetes                              | 1.26 (0.63−2.49) | 0.516 | 1.32 (0.68−2.55) | 0.412 |
| NIHSS on admission                    | 1.05 (0.98−1.13) | 0.132 | 1.04 (0.98−1.11) | 0.231 |
| Impaired consciousness                | 1.04 (0.53−2.04) | 0.904 | 1.18 (0.62−2.24) | 0.616 |
| Vomiting                              | 1.13 (0.55−2.32) | 0.739 | 1.93 (0.97−3.85) | 0.062 |
| Large MCA infarction                  | 2.53 (1.37−4.67) | 0.003 | 1.81 (1.02−3.21) | 0.044 |
| Osmotic therapy                       | 1.45 (0.65−3.25) | 0.369 | 1.54 (0.74−3.22) | 0.250 |
| Stroke-associated pneumonia           | 2.99 (1.40−6.40) | 0.005 | 3.01 (1.52−5.99) | 0.002 |

OR, odds ratio; CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; MCA, middle cerebral artery.
ability in study design, the differences were largely attributed to the severity of stroke, as stroke severity was a leading determinant of death. Our research subjects all had severe acute ischemic stroke, which likely explains the higher number of fatalities.

Dehydration has become a common concern after stroke. Although multiple indices could be applied to assess dehydration, such as blood urea nitrogen/creatinine ratio, urea/creatinine ratio, and plasma osmolality, there is no standard approach. The prevalence of dehydration after acute stroke ranges from 4.5% to 42% according to different evaluation indices and cutoffs. Our study showed that the incidence of dehydration (admission plasma osmolality >296 mOsm/kg) was 38.1%, which fell in the wide range mentioned above. Among various dehydration-related indices, plasma osmolality is sensitive and likely to be the best indicator for assessing dehydration state. Since the osmolality of human plasma is regulated by neuroendocrine mechanisms to a narrow range, a slight elevation in plasma osmolality could reflect compromised extracellular volume.

Currently, only a few studies have evaluated associations between plasma osmolality and mortality in stroke. Bhalla, et al. suggested that elevated plasma osmolality at admission results in 2.4-fold higher OR of 3-month mortality after stroke. In that work, the authors included 167 patients with acute stroke (89% ischemic stroke, 10% hemorrhagic stroke, 1% unclassified stroke). However, few studies have explored a uniform relationship with severe acute ischemic stroke. We demonstrated an independent association between elevated plasma osmolality and 3-month case fatality with a 1.98-fold higher OR. The result was similar with the previous study and confirmed that elevated plasma osmolality plays a role in predicting short-term case fatality in individuals with severe acute ischemic stroke. Moreover, we explored the association between admission plasma osmolality and 1-year case fatality after stroke. However, the association did not reach significance. As in another study, Ock and his colleagues explored the effects of hyperglycemia and hyperosmolality on clinical outcomes among ischemic stroke patients. They also failed to find an association for hyperosmolality (with or without hyperglycemia) or hyperglycemia alone with death either at discharge or at 6 months after stroke onset. Our and Ock’s studies may imply that elevated plasma osmolality more likely serves as a predictor of short-term case fatality, but not long-term case fatality, after stroke.

Several plausible mechanisms may explain how elevated plasma osmolality exerts fatal effects on stroke patients. First, hyperosmotic stress promotes the flow of water out of the cell, causing cell shrinkage. This dramatic change in cell morphology could disrupt crucial intracellular components, including the nucleus and mitochondrion, which would be accompanied by energy generation failure, as well as the activation of apoptotic signaling pathways and finally cell death. Second, elevated plasma osmolality as an inflammatory stimulus is often characterized by upregulation of inflammatory cytokines, such as TNF, IL-1β, IL-6, and IL-8. These components are strongly associated with ischemic stroke progression. Third, hyperosmolality reflects a state of inadequate hydration. Studies have shown that dehydration induces a decline in cerebral blood flow in the internal carotid and middle cerebral arteries without affecting the cerebral metabolic rate for oxygen. The absolute reduction of cerebral blood flow and relative increase in cerebral oxygen metabolism can aggravate existing brain damage after brain ischemia and finally result in poor outcomes.

Some limitations to this study need to be taken into consideration. First, our data were collected at a single center and analyzed retrospectively with a relatively small sample size. We first provided a clue that plasma osmolality may serve as a potential predictor for case fatality in severe acute ischemic stroke. Second, although many different calculated plasma osmolality equations could be used to assess dehydration status, there is no exclusive gold standard. Nonetheless, we chose A Khajuria’s equation to calculate plasma osmolality because it shows excellent concordance with measured osmolality.

In conclusion, we found elevated plasma osmolality, an indicator of dehydration, to be associated with increased risk of 3-month case fatality in severe acute ischemic stroke. However, we failed to find an association between elevated plasma osmolality and risk of 1-year case fatality. Further studies are needed to explore the relationship between plasma osmolality and long-term case fatality and to investigate whether pre-
vention of dehydration could improve survival after stroke.

ACKNOWLEDGEMENTS

This study was funded by the National Natural Science Foundation of China (Grant No.81974181), the 1-3-5 project for disciplines of excellence, West China Hospital, Sichuan University (No.ZYGJ18009) and the National Natural Science Foundation of China (Grant No. 82001250).

AUTHOR CONTRIBUTIONS

Conceptualization: Meng Liu. Data curation: Meng Liu. Formal analysis: Meng Liu. Funding acquisition: Ming Liu. Investigation: Meng Liu and Yilun Deng. Methodology: Meng Liu, Zilong Hao, and Simiao Wu. Project administration: Zilong Hao and Simiao Wu. Resources: Meng Liu. Software: Meng Liu. Supervision: Zilong Hao and Simiao Wu. Validation: Zilong Hao and Simiao Wu. Visualization: Yilun Deng and Yajun Cheng. Writing—original draft: Meng Liu. Writing—review & editing: Meng Liu, Zilong Hao, and Simiao Wu. Approval of final manuscript: all authors.

ORCID iDs

Meng Liu https://orcid.org/0000-0002-0548-8784
Yilun Deng https://orcid.org/0000-0002-7209-7855
Yajun Cheng https://orcid.org/0000-0002-5227-9811
Zilong Hao https://orcid.org/0000-0002-9754-4447
Simiao Wu https://orcid.org/0000-0001-4557-7386
Meng Liu https://orcid.org/0000-0001-9760-2806

REFERENCES

1. Katan M, Luft A. Global burden of stroke. Semin Neurol 2018;38: 208-11.
2. Wu S, Wu B, Liu M, Chen Z, Wang W, Anderson CS, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol 2019;18:394-405.
3. Mazya MV, Lees KR, Collas D, Rand VM, Mikulik R, Toni D, et al. IV thrombolysis in very severe and severe ischemic stroke: results from the SITS-ISTR registry. Neurology 2015;85:2098-106.
4. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R. ‘Malignant’ middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol 1996;53:309-15.
5. Schonewille WJ, Wijman CA, Michel P, Rueckert CM, Weimar C, Mattei HP, et al. Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BAICS): a prospective registry study. Lancet Neurol 2009;8:724-30.
6. Frank JJ. Large hemispheric infarction, deterioration, and intracranial pressure. Neurology 1995;45:1286-90.
7. Tao WD, Kong FY, Hao ZL, Lin S, Wang DR, Wu B, et al. One-year case fatality and disability after posterior circulation infarction in a Chinese hospital-based stroke study. Cerebrovasc Dis 2010;29: 376-81.
8. Saposnik G, Hill MD, O’Dunnell M, Fang J, Hachinski V, Kapral MK, et al. Variables associated with 7-day, 30-day, and 1-year fatality after ischemic stroke. Stroke 2008;39:2318-24.
9. Algın A, Inan I. The role of radiologic, clinical and biochemical parameters in prediction of stroke mortality. Neurosciences (Riyadh) 2019;24:110-4.
10. Rasouli M. Basic concepts and practical equations on osmolality: biochemical approach. Clin Biochem 2016;49:536-41.
11. Rodriguez GJ, Cordina SM, Vazquez G, Suri MF, Kirmani JF, Ezzeddine MA, et al. The hydration influence on the risk of stroke (THIRST) study. Neurocrit Care 2009;10:187-94.
12. Song SH, Kim JH, Lee JH, Yun YM, Choi DH, Kim HY. Elevated blood viscosity is associated with cerebral small vessel disease in patients with acute ischemic stroke. BMC Neurol 2017;17:20.
13. Chang SW, Huang YC, Lin LC, Yang JT, Weng HH, Tsai YH, et al. Effect of dehydration on the development of collaterals in acute middle cerebral artery occlusion. Eur J Neurol 2016;23:494-500.
14. Taitlisu MA, Kaya A, Keskin M, Uzman O, Borklu EB, Cinier G, et al. Can we use plasma hyperosmolality as a predictor of mortality for ST-segment elevation myocardial infarction? Coron Artery Dis 2017;28:70-6.
15. Kaya H, Yücel O, Ege MR, Zorlu A, Yücel H, Güneş H, et al. Plasma osmolality predicts mortality in patients with heart failure with reduced ejection fraction. Kardiol Pol 2017;75:316-22.
16. Kvistad CE, Novotny V, Kurz MW, Ranning OM, Thommessen B, Carlsson M, et al. Safety and outcomes of tenecteplase in moderate and severe ischemic stroke. Stroke 2019;50:1279-81.
17. Liu J, Zheng L, Cheng Y, Zhang S, Wu B, Wang D, et al. Trends in outcomes of patients with ischemic stroke treated between 2002 and 2016: insights from a Chinese cohort. Circ Cardiovasc Qual Outcomes 2019;12:e005610.
18. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864-70.
19. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018;49:e46-110.
20. Vahedi K, Vicaut E, Mateo J, Kurtz A, Orabi M, Guichard JP, et al. Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial). Stroke 2007;38:2506-17.
21. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:435-41.
22. Smith CJ, Kishore AK, Vail A, Chamorro A, Garau J, Hopkins SJ, et al. Diagnosis of stroke-associated pneumonia: recommendations from the pneumonia in stroke consensus group. Stroke 2015;46:2335-40.
23. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2937-44.
24. Khajuria A, Krahn J. Osmolality revisited—deriving and validating the best formula for calculated osmolality. Clin Biochem 2005;38: 514-9.
25. Martín-Calderón JL, Bustos F, Tuesta-Reina LR, Varona JM, Caballero L, Solano F. Choice of the best equation for plasma osmolality calculation: comparison of fourteen formulae. Clin Biochem 2015;48:529-33.
26. Sierra M, Bunn D, Prado CM, Hooper L. Accuracy of prediction equations for serum osmolality in frail older people with and without diabetes. Am J Clin Nutr 2014;100:867-76.
27. Weir N, Dennis MS; Scottish Stroke Outcomes Study Group. Towards a national system for monitoring the quality of hospital-based stroke services. Stroke 2001;32:1415-21.
28. Di Carlo A, Inzitari D, Galati F, Baldereschi M, Giunta V, Grillo G, et al. A prospective community-based study of stroke in Southern
Italy: the Vibo Valentia incidence of stroke study (VISS). Methodology, incidence and case fatality at 28 days, 3 and 12 months. Cerebrovasc Dis 2003;16:410-7.
29. Bahouth MN, Gottesman RF, Szanton SL. Primary ‘dehydration’ and acute stroke: a systematic research review. J Neurol 2018;265:2167-81.
30. Cortés-Vicente E, Guisado-Alonso D, Delgado-Mederos R, Camps-Renom P, Prats-Sánchez L, Martínez-Domeño A, et al. Frequency, risk factors, and prognosis of dehydration in acute stroke. Front Neurol 2019;10:305.
31. Schrock JW, Glasenapp M, Drogell K. Elevated blood urea nitrogen/creatinine ratio is associated with poor outcome in patients with ischemic stroke. Clin Neurol Neurosurg 2012;114:881-4.
32. Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab 2003;17:471-503.
33. Bhalla A, Sankaralingam S, Dundas R, Swaminathan R, Wolfe CD, Rudd AG. Influence of raised plasma osmolality on clinical outcome after acute stroke. Stroke 2000;31:2043-8.
34. Ock S, Jo S, Lee JB, Jin Y, Jeong T, Yoon J, et al. Comprehensive interpretation of hyperglycemia and hyperosmolality on the clinical outcomes among ischemic stroke patients. Am J Emerg Med 2016;34:2343-50.
35. Burg MB, Ferraris JD, Dmitrieva NI. Cellular response to hyperosmotic stresses. Physiol Rev 2007;87:1441-74.
36. Reinehr R, Häussinger D. Hyperosmotic activation of the CD95 death receptor system. Acta Physiol (Oxf) 2006;187:199-203.
37. Dmitrieva NI, Michea LF, Rocha GM, Burg MB. Cell cycle delay and apoptosis in response to osmotic stress. Comp Biochem Physiol A Mol Integr Physiol 2001;130:411-20.
38. Schwartz L, Guais A, Pooya M, Abolhassani M. Is inflammation a consequence of extracellular hyperosmolality? J Inflamm (Lond) 2009;6:21.
39. Watso JC, Farquhar WB. Hydration status and cardiovascular function. Nutrients 2019;11:1866.
40. Tsai YH, Yang JL, Lee IN, Yang JT, Lin LC, Huang VC, et al. Effects of dehydration on brain perfusion and infarct core after acute middle cerebral artery occlusion in rats: evidence from high-field magnetic resonance imaging. Front Neurol 2018;9:786.